Annals of Diagnostic Pathology
Volume 14, Issue 1 , Pages 23-29 , February 2010

Clinicopathological implications of expressions of hypoxia-related molecules in esophageal superficial squamous cell carcinoma

  • Naoki Ogane, PhD

      Affiliations

    • Division of Pathology, Kanagawa Cancer Center Hospital, Kanagawa 241-0815, Japan
    • ,
  • Masanori Yasuda, MD, PhD

      Affiliations

    • Department of Pathology, Saitama Medical University International Medical Center, Saitama 350-1298, Japan
    • Corresponding Author InformationCorrespondence author. Tel.: +81 42 984 0609; fax: +81 42 984 0609.
    • ,
  • Michio Shimizu, MD, PhD

      Affiliations

    • Department of Pathology, Saitama Medical University International Medical Center, Saitama 350-1298, Japan
    • ,
  • Masaki Miyazawa, PhD

      Affiliations

    • Department of Pathology, Tokai University School of Medicine, Kanagawa 259-1193, Japan
    • ,
  • Shingo Kamoshida, PhD

      Affiliations

    • Laboratory of Pathology, Division of Medical Biophysics, Kobe University Graduate School of Health Sciences, Kobe 654-0142, Japan
    • ,
  • Akiko Ueda, MD, PhD

      Affiliations

    • Division of Pathology, Kanagawa Cancer Center Hospital, Kanagawa 241-0815, Japan
    • ,
  • Ken Takata, MD, PhD

      Affiliations

    • Division of Surgery, Kanagawa Cancer Center Hospital, Kanagawa 241-0815, Japan
    • ,
  • Yuji Sakuma, MD, PhD

      Affiliations

    • Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Kanagawa 241-0815, Japan
    • ,
  • Yohei Miyagi, MD, PhD

      Affiliations

    • Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Kanagawa 241-0815, Japan
    • ,
  • Yoichi Kameda, MD, PhD

      Affiliations

    • Division of Pathology, Kanagawa Cancer Center Hospital, Kanagawa 241-0815, Japan

References 

  1. Takubo K, Aida J, Sawade M, et al. Early squamous cell carcinoma of oesophagus: the Japanese viewpoint. Histopathology. 2007;51:733–742
  2. Japan Esophageal Society . Japanese Classification of Esophageal Cancer, 10th. Tokyo Japan: Kanehara Co., Ltd.; 2007;
  3. Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med. 2002;70:1841–1843
  4. Yasuda M, Miyazawa M, Fujita M, et al. Expression of hypoxia-inducible factor-1α (HIF-1α) and glucose transporter-1 (GLUT-1) in ovarian adenocarcinomas: Difference in hypoxic status depending on histological character. Oncol Rep. 2007;19:111–116
  5. Iida T, Yasuda M, Miyazawa M, et al. Hypoxic status in ovarian serous and mucinous tumors: Relationship between histological characteristics and HIF-1 alpha/GLUT-1 expression. Arch Gynecol Obstet. 2008;277:539–546
  6. Yasuda M, Ogane N, Hayashi H, et al. Glucose transporter-1 expression in the thyroid gland: Clinicopathological significance for papillary carcinoma. Oncol Rep. 2005;14:1499–1504
  7. Haber RS, Rathan A, Weiser KR, et al. GLUT-1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer. 1998;83:34–40
  8. Ogawa J, Inoue H, koide S. Glucouse-transporter-type-I-gene amplification correlates with sialyl-Lewis-X synthesis and proliferation in lung cancer. Int J Cancer. 1997;74:189–192
  9. Cantuaria G, Fagotti A, Ferranina G, et al. GLUT-1 expression in ovarian carcinoma: association with survial and response to chemotherapy. Cancer. 2001;92:1144–1150
  10. Kuwamura T, Kusakabe T, Sugino T, et al. Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer. 2001;92:634–641
  11. Nobes C, Hall A. Regulation and function of the Rho subfamily of small GTPases. Curr Opin Genet Dev. 1994;4:77–81
  12. Qiu RG, Chen J, McCormick F, et al. A role for Rho in Ras transformation. Proc Natl Acad Sci U S A. 1995;92:11781–11785
  13. Roux P, Gauthier-Rouviere C, Doucet-Brutin S, et al. The small GTPases Cdc42Hs, Rac1 and RhoG delineate Raf-independent pathways that cooperate to transform NIH3T3 cells. Curr Biol. 1997;7:629–637
  14. Clark EA, Golub TR, Lander ES, et al. Genomic analysis of metastasis reveals an essential role for RhoC. Nature. 2000;406:532–535
  15. Ridley AJ. Rho GTPases and cell migration. J Cell Sci. 2001;114:2713–2722
  16. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13:1501–1512
  17. Robles AI, Rodriguez-puebla ML, Glick AB, et al. Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo. Genes Dev. 1998;12:2469–2474
  18. Coleman ML, Olson MF. Rho GTPase signaling pathways in the morphological changes associated with apoptosis. Cell Death Differ. 2002;9:493–504
  19. Pervaiz S, Cao J, Chao OS, et al. Activation of the Rac GTPase inhibits apoptosis in human tumor cells. Oncogene. 2001;20:6263–6268
  20. Xue Y, Bi F, Zhang X, et al. Role of Rac1 and Cdc42 in hypoxia induced p53 and von Hippel-Lindau suppression and HIF1α activation. Int j Cancer. 2006;118:2965–2972
  21. Turcotte S, Desrosiers RR, Béliveau R. HIF-1alpha mRNA and protein upregulation involves Rho GTPase expression during hypoxia in renal cell carcinoma. J Cell Sci. 2003;116:2247–2260
  22. Hirota K, Semenza GL. Rac1 activity is required for the activation of hypoxia-inducible factor 1. J Biol Chem. 2001;24:21166–21172
  23. Kurokawa T, Miyamoto M, Kato K, et al. Overexpression of hypoxia-inducible factor-1 (HIF-1α) in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Br J Cancer. 2003;89:1042–1047
  24. Matsuyama T, Nakanishi K, Hayashi T, et al. Expression of hypoxia-inducible factor–1α in esophageal squamous cell carcinoma. Cance Sci. 2005;96:176–182
  25. Koukourakis MI, Giatromanolaki A, Skarlatos J, et al. Hypoxia inducible factor (HIF-1a and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res. 2001;61:1830–1832
  26. Tohoma T, Okazumi S, Makino H, et al. Overexpression of glucose transporter 1 in esophageal squamous cell carcinoma: a marker for poor prognosis. Dis Esophagus. 2005;18:185–189
  27. Kato H, Takita J, Miyazaki T, et al. Glut-1 glucose transporter expression in esophageal squamous cell carcinoma is associated with tumor aggressiveness. Anticancer Res. 2002;22:2635–2640
  28. Chino O, Kijima H, Shimada H, et al. Accumulation of p53 in esophageal squamous cell carcinoma. Int J Mol Med. 2001;8:359–363
  29. Hara T, Kijima H, Yamamoto S, et al. Ubiquitous p63 expression in human esophageal squamous cell carcinoma. Int J Mol Med. 2004;14:169–173
  30. Nadaoka J, Horikawa Y, Saito M, et al. Prognostic significance of HIF-1 alpha polymorphisms in transitional cell carcinoma of the bladder. Int J Cancer. 2008;122:1297–1302
  31. Sun HC, Qiu ZJ, Liu J, et al. Expression of hypoxia-inducible factor-1 alpha and associated proteins in pancreatic ductal adenocarcinoma and their impact on prognosis. J Oncol. 2007;30:1359–1367
  32. Mizokami K, Kakeji Y, Oda S, et al. Clinicopathologic significance of hypoxia-inducible factor 1alpha overexpression in gastric carcinomas. J Surg Oncol. 2006;94:149–154
  33. Klatte T, Seligson DB, Riggs SB, et al. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res. 2007;13:7388–7393
  34. Bos R, van Diest PJ, van der Groep P, et al. Expression of hypoxia-inducible factor-1alpha and cell cycle proteins in invasive breast cancer are estrogen receptor related. Breast Cancer Res. 2004;6:450–459
  35. Osada R, Horiuchi A, Kikuchi N, et al. Expression of hypoxia-inducible factor 1 alpha, hypoxia-inducible factor 2 alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1 alpha is an independent prognostic factor in ovarian carcinoma. Hum Pathol. 2007;38:310–320
  36. Birner P, Schindl M, Obermair A, et al. Expression of hypoxia-inducible factor 1 alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Cancer Res. 2000;60:4610–4616
  37. Nakayama K, Kanzaki A, Hata K, et al. Hypoxia-inducible factor 1 alpha (HIF-1 alpha) gene expression in human ovarian carcinoma. Cancer Lett. 2002;176:215–223
  38. Miyazawa M, Yasuda M, Fujita M, et al. Therapeutic strategy targeting at mTOR-HIF-1α-VEGF pathway for ovarian clear cell adenocarcinoma. Pathol Int. 2009;59:19–27
  39. Miyazawa M, Yasuda M, Fujita M, et al. Association of hypoxia-inducible factor-1 expression with histology in epithelial ovarian tumors: a quantitative analysis of HIF-1. Arch Gynecol Obstet. 2009;279:789–796
  40. Zohn IM, Campbell SL, Khosravi-far R, et al. Rho family proteins and Ras transformation: RHad less traveled gets congested. Oncogene. 1998;17:1415–1438
  41. Liu SY, Yen CY, Yang SC, et al. Overexpression of Rac-1 Small GTPase Binding Protein in Oral Squamous cell Carcinoma. J Oral Maxillofac Surg. 2004;62:702–707

PII: S1092-9134(09)00123-3

doi: 10.1016/j.anndiagpath.2009.10.003

Annals of Diagnostic Pathology
Volume 14, Issue 1 , Pages 23-29 , February 2010

Article Tools

* Image Usage & Resolution